Wall Street analysts expect Tyme Technologies Inc (NASDAQ:TYME) to report ($0.08) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Tyme Technologies’ earnings. Tyme Technologies reported earnings of ($0.06) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 33.3%. The business is expected to report its next quarterly earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Tyme Technologies will report full-year earnings of ($0.32) per share for the current financial year. For the next fiscal year, analysts expect that the firm will report earnings of ($0.38) per share. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Tyme Technologies.
Several analysts have recently commented on TYME shares. BidaskClub upgraded Tyme Technologies from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 27th. Zacks Investment Research upgraded Tyme Technologies from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Friday, August 10th. Canaccord Genuity set a $10.00 target price on Tyme Technologies and gave the company a “buy” rating in a research note on Tuesday, July 31st. Finally, HC Wainwright restated a “buy” rating and issued a $9.50 target price on shares of Tyme Technologies in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $7.31.
Several institutional investors and hedge funds have recently modified their holdings of TYME. Rhumbline Advisers bought a new position in Tyme Technologies in the 2nd quarter valued at about $110,000. Ardsley Advisory Partners lifted its position in Tyme Technologies by 10.5% in the 2nd quarter. Ardsley Advisory Partners now owns 1,033,500 shares of the company’s stock valued at $3,266,000 after acquiring an additional 98,500 shares in the last quarter. Perkins Capital Management Inc. lifted its position in Tyme Technologies by 330.0% in the 2nd quarter. Perkins Capital Management Inc. now owns 101,050 shares of the company’s stock valued at $319,000 after acquiring an additional 77,550 shares in the last quarter. Millennium Management LLC lifted its position in Tyme Technologies by 551.5% in the 1st quarter. Millennium Management LLC now owns 1,551,315 shares of the company’s stock valued at $3,459,000 after acquiring an additional 1,313,190 shares in the last quarter. Finally, Northern Trust Corp bought a new position in Tyme Technologies in the 2nd quarter valued at about $1,181,000. Institutional investors own 11.13% of the company’s stock.
Shares of TYME traded down $0.10 during trading hours on Wednesday, hitting $2.53. The stock had a trading volume of 187,207 shares, compared to its average volume of 295,916. The company has a market cap of $281.41 million, a PE ratio of -12.05 and a beta of 0.18. Tyme Technologies has a 1-year low of $2.01 and a 1-year high of $8.30.
About Tyme Technologies
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Recommended Story: Dividend Stocks – Are They Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.